[Hepatic arterial infusion of etoposide in the treatment of primary liver neoplasms].
A phase 1 study of etoposide for hepatocellular carcinoma and cholangiocarcinoma was undertaken by single arterial infusion (9 cases; range of doses levels; step 1: 50 mg/m2, step 2: 75 mg/m2, step 3: 120 mg/m2). Mild leukopenia (2500/mm3 in step 2 and 2400/mm3 in step 3) was observed in 2 cases. Thrombocytopenia or anemia was not observed in these doses. Hypotension was experienced 2 hrs. after infusion in one case of step 2. The post-infusion plasma decay of etoposide was biphasic with t1/2 alpha ranging from 0.59 approximately 0.63 h and t1/2 beta ranging from 5.40 approximately 6.57 h. AUC0-24 increased in association with the increase of the doses. Hepatic artery infusion of etoposide was performed without serious complication and the dose limiting toxicity was leukopenia.
Yasuda
H
H
Division of Gastroenterology, Mitsui Memorial Hospital.
Fujino
H
H
Tagawa
K
K
Unuma
T
T
D002759:Adenoma, Bile Duct / Q000188:drug therapy / Q000378:metabolism; D001650:Bile Duct Neoplasms / Q000188:drug therapy / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005047:Etoposide / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged
D005047:Etoposide